Correlation Between Reviva Pharmaceuticals and Allogene Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Reviva Pharmaceuticals and Allogene Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Reviva Pharmaceuticals and Allogene Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Reviva Pharmaceuticals Holdings and Allogene Therapeutics, you can compare the effects of market volatilities on Reviva Pharmaceuticals and Allogene Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Reviva Pharmaceuticals with a short position of Allogene Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Reviva Pharmaceuticals and Allogene Therapeutics.

Diversification Opportunities for Reviva Pharmaceuticals and Allogene Therapeutics

-0.6
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Reviva and Allogene is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding Reviva Pharmaceuticals Holding and Allogene Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allogene Therapeutics and Reviva Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Reviva Pharmaceuticals Holdings are associated (or correlated) with Allogene Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allogene Therapeutics has no effect on the direction of Reviva Pharmaceuticals i.e., Reviva Pharmaceuticals and Allogene Therapeutics go up and down completely randomly.

Pair Corralation between Reviva Pharmaceuticals and Allogene Therapeutics

Given the investment horizon of 90 days Reviva Pharmaceuticals Holdings is expected to generate 1.68 times more return on investment than Allogene Therapeutics. However, Reviva Pharmaceuticals is 1.68 times more volatile than Allogene Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Allogene Therapeutics is currently generating about -0.05 per unit of risk. If you would invest  438.00  in Reviva Pharmaceuticals Holdings on October 7, 2024 and sell it today you would lose (248.00) from holding Reviva Pharmaceuticals Holdings or give up 56.62% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Reviva Pharmaceuticals Holding  vs.  Allogene Therapeutics

 Performance 
       Timeline  
Reviva Pharmaceuticals 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Allogene Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allogene Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Reviva Pharmaceuticals and Allogene Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Reviva Pharmaceuticals and Allogene Therapeutics

The main advantage of trading using opposite Reviva Pharmaceuticals and Allogene Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Reviva Pharmaceuticals position performs unexpectedly, Allogene Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will offset losses from the drop in Allogene Therapeutics' long position.
The idea behind Reviva Pharmaceuticals Holdings and Allogene Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk